Company profile
GENMAB A/S
NASDAQ:GMABBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Golcadomide | phase2 | — | 5 | active |
| Tixestobart | phase1_2 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (66)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06771921 | phase1_2 | terminated | 2025-01-29 | 2025-06-11 | Genmab | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors |
| NCT06018129 | phase1_2 | terminated | 2023-09-21 | 2025-02-05 | Genmab | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma |
| NCT07695831 | phase1 | recruiting | 2026-08-13 | 2029-06-01 | Genmab | A Phase 1 Trial of GEN1119 in Participants With Solid Tumors |
| NCT06685068 | phase1_2 | terminated | 2024-11-13 | 2026-03-30 | Genmab | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors |
| NCT04628494 | phase3 | active_not_recruiting | 2021-01-13 | 2025-10-13 | Genmab | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761324 | BLA | Genmab US, Inc. | ||||
Loading… | ||||||